NAUTNAUTILUS BIOTECHNOLOGY, INC.Small cap · $226.2M · FY ending 2025-12-31
$1.78-5.82% · 2026-07-13 · EOD
51/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality—
margins & F-ScoreValue33
valuation vs its own rangeMomentum52
golden · price below 200-daySmart Money69
buying · 0 funds · 1P/1S insidersMixed trendGolden crossBelow 200-day
vs S&P 500-28.5%
6-mo excess Trailing performance1M -21.2%
3M -39.7%
6M -19.8%
YTD -6.8%
1Y +136.7%
Not enough profitable-period data to value NAUT on earnings.
ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.
Net buying1P / 1S insiders · 0 funds hold · 0 Congress buys
Recent insidersAH Equity Partners Bio II, L.L.C. · 10% ownerSELL$11.8M
Patel Sujal M · CEO, President, and SecretaryBUY$65,238
Fhealth · 24/100
May need capital~3 months of cash left — critical · burning $12.7M / quarter
- ●Short cash runway Burning cash with roughly 3 months of runway — a dilutive raise looks likely.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.